Baxter International (BAX) Shares are Up 4.86%

Baxter International (BAX) : Traders are bullish on Baxter International (BAX) as it has outperformed the S&P 500 by a wide margin of 0.64% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 4.3%, relative to the S&P 500. The stock has risen by 4.86% in the past week indicating that the buyers are active at lower levels, but the stock is down -1.4% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 1.44% and the 50-Day Moving Average is 0.44%.The 200 Day SMA reached 12.46% Baxter International Inc. is up 6.69% in the last 3-month period. Year-to-Date the stock performance stands at 25.01%.


Baxter International (BAX) : 8 Wall Street analysts covering Baxter International (BAX) believe that the average level the stock could reach for the short term is $50.75. The maximum price target given is $60 and the minimum target for short term is around $47, hence the standard deviation is calculated at $4.23.

Company shares have received an average consensus rating of Hold for the current week Baxter International (NYSE:BAX): The stock opened at $47.09 and touched an intraday high of $47.4 on Friday. During the day, the stock corrected to an intraday low of $46.75, however, the bulls stepped in and pushed the price higher to close in the green at $47.28 with a gain of 0.45% for the day. The total traded volume for the day was 14,556,977. The stock had closed at $47.07 in the previous trading session.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.